Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: Study of 6 cases;Eficacia de tacrolimus (FK-506) en el tratamiento de las formas graves de dermatomiositis infantil: Estudio de 6 casos

Medicina Clinica

Volumn 127, Issue 18, 2006, Pages 697-701

  Nalda, Andrea Martín ^a   Caballero, Consuelo Modesto ^a   Guimeral, Cristina Arnal ^a   Rom, Mercedes Boronat ^a   García, Pedro Barceló ^b  

^a HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Juvenile dermatomyositis; Skin damage; Tacrolimus (FK 506)

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MEPREDNISONE; METHOTREXATE; PREDNISONE; TACROLIMUS;

ARTICLE; CHILD; CLINICAL ARTICLE; DERMATOMYOSITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; MALE; MEDICAL RECORD; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 33845999545     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(06)72367-3     Document Type: Article

References (27)

1. Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34:732-6.
2. Méndez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al; NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49:300-5.
3. Martini G, Calabrese F, Biscaro F, Zulian F. A child with dermatomyositis and a suspicious lymphadenopathy. J Rheumatol. 2005;32:744-6.
4. Compeyrot-Lacassagne S, Feldman BM. Inflammatory myopathies in children. Pediatr Clin North Am. 2005;52:493-520.
5. Fedczyna TO, Lutz J, Pachman LM. Expression of TNFα by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFα-308A allele. Clin Immunol. 2001;100:236-9.
6. Crowson AN, Magro CM, Dawood MR. A causal role for parvovirus B19 infection in adult dermatomyositis and other autoimmune syndromes. J Cutan Pathol. 2000;27:505-15.
7. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344-7.
8. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:403-7.
9. 2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford). 2004;43:603-8.
10. Ng YT, Ouvrier RA, Wu T. Drug therapy in juvenile dermatomyositis: follow-up study. J Child Neurol. 1998;13:109-12.
11. Mastaglia FL, Zilko PJ. Inflammatory myopathies: how to treat the difficult cases. J Clin Neurosci. 2003;10:99-101.
12. Heckmatt J, Saunders C, Peters AM, Rose M, Hasson N, Thompson N, et al. Cyclosporin in juvenile dermatomiositis. Lancet. 1989;1(8646): 1063-6.
13. Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997;24: 2436-43.
14. Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004;43:491-6.
15. Sinoway PA, Callen JP. Chlorambucil: an effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 1993;36:325-8.
16. Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142:65-9.
17. Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/ dermatomyositis. Ann Rheum Dis. 2002;61:37-41.
18. Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol. 2005;141: 855-9.
19. Buka RL, Cunningham BB. Connective tissue disease in children. Pediatr Ann. 2005;34:225-9.
20. Shehata R, Al-Mayouf S, Al-Dalaan A, Al-Mazaid A, Al-Balaa S, Bahabri S. Juvenile dermatomyositis: clinical profile and disease course in 25 patients. Clin Exp Rheumatol. 1999;17:115-8.
21. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103:882-8.
22. Scott U, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003; 63:1247-97.
23. th ed. Baltimore: Williams and Wilkins; 1993.
24. Isenberg D, Rider LG, Ehrenstein M. Development of disease activity and damage indices for myositis: initial testing of four tools in adult onset patients. Arthritis Rheum. 2001;44:263.
25. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971-82.
26. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, et al. Paediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford). 2003;42:1452-9.
27. Rider LG, Giannini EH, Brunner HI, Ruperto N, Newton L, Reed A, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004;50: 2281-90.